Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice†
Xing Yu(Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine), Sanjay Bhanot(Ionis Pharmaceuticals (United States)), Xiu‐Zhen Song(Ionis Pharmaceuticals (United States)), Robert A. McKay(Ionis Pharmaceuticals (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States)), Songyuan Chen(Ionis Pharmaceuticals (United States)), Sanjay K. Pandey(Ionis Pharmaceuticals (United States)), Susan F. Murray(Abbott (United States)), Susan Kelly(Ionis Pharmaceuticals (United States)), Dingjiu Bao(Ionis Pharmaceuticals (United States)), Sheri Booten(Ionis Pharmaceuticals (United States))
Cited by 303
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
|Hepatology|2007|1k
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
|Journal of Biological Chemistry|1993|770